抄録
Importance: The incidence of early-onset colorectal cancer (younger than 50 years) is rising globally, the reasons for which are unclear. It appears to represent a unique disease process with different clinical, pathological, and molecular characteristics compared with late-onset colorectal cancer. Data on oncological outcomes are limited, and sensitivity to conventional neoadjuvant and adjuvant therapy regimens appear to be unknown. The purpose of this review is to summarize the available literature on early-onset colorectal cancer. Observations: Within the next decade, it is estimated that 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in adults younger than 50 years. Potential risk factors include a Westernized diet, obesity, antibiotic usage, and alterations in the gut microbiome. Although genetic predisposition plays a role, most cases are sporadic. The full spectrum of germline and somatic sequence variations implicated remains unknown. Younger patients typically present with descending colonic or rectal cancer, advanced disease stage, and unfavorable histopathological features. Despite being more likely to receive neoadjuvant and adjuvant therapy, patients with early-onset disease demonstrate comparable oncological outcomes with their older counterparts. Conclusions and Relevance: The clinicopathological features, underlying molecular profiles, and drivers of early-onset colorectal cancer differ from those of late-onset disease. Standardized, age-specific preventive, screening, diagnostic, and therapeutic strategies are required to optimize outcomes.
本文言語 | English |
---|---|
ページ(範囲) | 865-874 |
ページ数 | 10 |
ジャーナル | JAMA Surgery |
巻 | 156 |
号 | 9 |
DOI | |
出版ステータス | Published - 2021 9月 |
ASJC Scopus subject areas
- 外科
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
フィンガープリント
「Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA Surgery, Vol. 156, No. 9, 09.2021, p. 865-874.
研究成果: Review article › 査読
}
TY - JOUR
T1 - Characteristics of Early-Onset vs Late-Onset Colorectal Cancer
T2 - A Review
AU - Zaborowski, Alexandra M.
AU - Abdile, Ahmed
AU - Adamina, Michel
AU - Aigner, Felix
AU - D'Allens, Laura
AU - Allmer, Caterina
AU - Álvarez, Andrea
AU - Anula, Rocio
AU - Andric, Mihailo
AU - Atallah, Sam
AU - Bach, Simon
AU - Bala, Miklosh
AU - Barussaud, Marie
AU - Bausys, Augustinas
AU - Bebington, Brendan
AU - Beggs, Andrew
AU - Bellolio, Felipe
AU - Bennett, Melissa Rose
AU - Berdinskikh, Anton
AU - Bevan, Vicki
AU - Biondo, Sebastiano
AU - Bislenghi, Gabriele
AU - Bludau, Marc
AU - Boutall, Adam
AU - Brouwer, Nelleke
AU - Brown, Carl
AU - Bruns, Christiane
AU - Buchanan, Daniel D.
AU - Buchwald, Pamela
AU - Burger, Jacobus W.A.
AU - Burlov, Nikita
AU - Campanelli, Michela
AU - Capdepont, Maylis
AU - Carvello, Michele
AU - Chew, Hwee Hoon
AU - Christoforidis, Dimitri
AU - Clark, David
AU - Climent, Marta
AU - Cologne, Kyle G.
AU - Contreras, Tomas
AU - Croner, Roland
AU - Daniels, Ian R.
AU - Dapri, Giovanni
AU - Davies, Justin
AU - Delrio, Paolo
AU - Denost, Quentin
AU - Deutsch, Michael
AU - Dias, Andre
AU - D'Hoore, André
AU - Drozdov, Evgeniy
AU - Duek, Daniel
AU - Dunlop, Malcolm
AU - Dziki, Adam
AU - Edmundson, Aleksandra
AU - Efetov, Sergey
AU - El-Hussuna, Alaa
AU - Elliot, Brodie
AU - Emile, Sameh
AU - Espin, Eloy
AU - Evans, Martyn
AU - Faes, Seraina
AU - Faiz, Omar
AU - Fleming, Fergal
AU - Foppa, Caterina
AU - Fowler, George
AU - Frasson, Matteo
AU - Figueiredo, Nuno
AU - Forgan, Tim
AU - Frizelle, Frank
AU - Gadaev, Shamil
AU - Gellona, Jose
AU - Glyn, Tamara
AU - Gong, Jianping
AU - Goran, Barisic
AU - Greenwood, Emma
AU - Guren, Marianne G.
AU - Guillon, Stephanie
AU - Gutlic, Ida
AU - Hahnloser, Dieter
AU - Hampel, Heather
AU - Hanly, Ann
AU - Hasegawa, Hirotoshi
AU - Iversen, Lene Hjerrild
AU - Hill, Andrew
AU - Hill, James
AU - Hoch, Jiri
AU - Hoffmeister, Michael
AU - Hompes, Roel
AU - Hurtado, Luis
AU - Iaquinandi, Fabiano
AU - Imbrasaite, Ugne
AU - Islam, Rumana
AU - Jafari, Mehrenah Dorna
AU - Kanemitsu, Yukihide
AU - Karachun, Aleksei
AU - Karimuddin, Ahmer A.
AU - Keller, Deborah S.
AU - Kelly, Justin
AU - Kennelly, Rory
AU - Khrykov, Gleb
AU - Kocian, Peter
AU - Koh, Cherry
AU - Kok, Neils
AU - Knight, Katrina A.
AU - Knol, Joep
AU - Kontovounisios, Christos
AU - Korner, Hartwig
AU - Krivokapic, Zoran
AU - Kronberger, Irmgard
AU - Kroon, Hidde Maarten
AU - Kryzauskas, Marius
AU - Kural, Said
AU - Kusters, Miranda
AU - Lakkis, Zaher
AU - Lankov, Timur
AU - Larson, Dave
AU - Lázár, György
AU - Lee, Kai Yin
AU - Lee, Suk Hwan
AU - Lefèvre, Jérémie H.
AU - Lepisto, Anna
AU - Lieu, Christopher
AU - Loi, Lynette
AU - Lynch, Craig
AU - Maillou-Martinaud, Helene
AU - Maroli, Annalisa
AU - Martin, Sean
AU - Martling, Anna
AU - Matzel, Klaus E.
AU - Mayol, Julio
AU - McDermott, Frank
AU - Meurette, Guillaume
AU - Millan, Monica
AU - Mitteregger, Martin
AU - Moiseenko, Andrei
AU - Monson, John R.T.
AU - Morarasu, Stefan
AU - Moritani, Konosuke
AU - Möslein, Gabriela
AU - Munini, Martino
AU - Nahas, Caio
AU - Nahas, Sergio
AU - Negoi, Ionut
AU - Novikova, Anastasia
AU - Ocares, Misael
AU - Okabayashi, Koji
AU - Olkina, Alexandra
AU - Oñate-Ocaña, Luis
AU - Otero, Jaime
AU - Ozen, Cihan
AU - Pace, Ugo
AU - São Julião, Guilherme Pagin
AU - Panaiotti, Lidiia
AU - Panis, Yves
AU - Papamichael, Demetris
AU - Park, Jason
AU - Patel, Swati
AU - Patrón Uriburu, Juan Carlos
AU - Pera, Miguel
AU - Perez, Rodrigo O.
AU - Petrov, Alexei
AU - Pfeffer, Frank
AU - Phang, P. Terry
AU - Poskus, Tomas
AU - Pringle, Heather
AU - Proud, David
AU - Raguz, Ivana
AU - Rama, Nuno
AU - Rasheed, Shahnawaz
AU - Raval, Manoj J.
AU - Rega, Daniela
AU - Reissfelder, Christoph
AU - Reyes Meneses, Juan Carlos
AU - Ris, Frederic
AU - Riss, Stefan
AU - Rodriguez-Zentner, Homero
AU - Roxburgh, Campbell S.
AU - Saklani, Avanish
AU - Salido, Andrea Jiménez
AU - Sammour, Tarik
AU - Saraste, Deborah
AU - Schneider, Martin
AU - Seishima, Ryo
AU - Sekulic, Aleksandar
AU - Seppala, Toni
AU - Sheahan, Kieran
AU - Shine, Rebecca
AU - Shlomina, Alexandra
AU - Sica, Guiseppe S.
AU - Singnomklao, Tongplaew
AU - Siragusa, Leandro
AU - Smart, Neil
AU - Solis, Alejandro
AU - Spinelli, Antonino
AU - Staiger, Roxane D.
AU - Stamos, Michael J.
AU - Steele, Scott
AU - Sunderland, Michael
AU - Tan, Ker Kan
AU - Tanis, Pieter J.
AU - Tekkis, Paris
AU - Teklay, Biniam
AU - Tengku, Sabrina
AU - Jiménez-Toscano, Marta
AU - Tsarkov, Petr
AU - Turina, Matthias
AU - Ulrich, Alexis
AU - Vailati, Bruna B.
AU - Van Harten, Meike
AU - Verhoef, Cornelis
AU - Warrier, Satish
AU - Wexner, Steve
AU - De Wilt, Hans
AU - Weinberg, Benjamin A.
AU - Wells, Cameron
AU - Wolthuis, Albert
AU - Xynos, Evangelos
AU - You, Nancy
AU - Zakharenko, Alexander
AU - Zeballos, Justino
AU - Winter, Des C.
N1 - Funding Information: reported grants from Medical Research Council South Africa as part of a Medical Research Council CURE grant and personal fees from Wits Consortium Salary as a past head of colorectal surgery during the conduct of the study; also, as a researcher in the developing world, Dr Bebington is constantly seeking opportunities to collaborate with institutions such as the Sloan Kettering, which has not unduly affected the honesty of data provided for the research nor the contribution he has made to intellectual content but could be construed as such. Dr Bruns reported personal fees from Medtronic as an advisory board member and Promedicis for Excellence in Oncology and grants from Intuitive for the ESOMAP trial and SIRTex for the ESSURE registry outside the submitted work. Dr Daniels reported personal fees from Origin Sciences, where he is a chief medical officer, appointed in August 2020; personal fees from Medtronic/Covidien and BD/Bard for teaching and advising; and nonfinancial support from Colostomy UK as honorary president of a charity focused on support for people with stomas, outside the submitted work. Dr Dunlop reported grants from University of Edinburgh during the conduct of the study. Dr Fleming reported author royalties from UptoDate outside the submitted work. Dr Frasson reported personal fees from J&J Consultory outside the submitted work. Dr Figueiredo reported personal fees for consulting and lectures from Johnson & Johnson outside the submitted work. Dr Frizelle reported serving as the editor of another Journal. Dr Hampel reported advisory board membership with Invitae Scientific, Genome Medical Scientific, and Promega Scientific outside the submitted work. Dr Karimuddin reported speaker’s fees from Servier outside the submitted work. Dr Lynch reported proctoring fees from Device Technologies and honoraria from Stryker outside the submitted work. Dr Mayol reported personal fees from Novartis, Boehringer Ingelheim, Astellas, Rovi, SOBI, Shionogi, Alcon, Roche, and Johnson & Johnson outside the submitted work. Dr São Julião reported personal fees from Johnson and Johnson, Roche, and Merck Sharp & Dohme outside the submitted work. Dr Pfeffer reported a research grant from Intuitive Surgical outside the submitted work. Dr Ris reported personal fees from Arthrex, Distal Motion, and Stryker and grants from Quantgene outside the submitted work. Dr Saraste reported grants from Bengt Ihre Foundation and Mag-Tarmfonden during the conduct of the study. Dr Seppälä reported being the CEO and co-owner from Healthfund Finland Ltd and interview honoraria from Boehringer Ingelheim Finland outside the submitted work. Dr Smart reported personal fees (speaker’s fees for hernia surgery) from Medtronic and WL Gore outside the submitted work. Dr Spinelli reported personal fees from Ethicon, Takeda, Janssen, Sofar, and Oasis outside the submitted work. Dr Tanis reported grants from LifeCell and Allergan outside the submitted work. Dr Vailati reported personal fees from Medtronic and Johnson & Johnson outside the submitted work. Dr Wexner reported consulting fees from Intuitive Surgical, Stryker, Medtronic, Tigenix, Axonics, Baxter, LiCor, and AISChannel; stock options from Regentys, LifeBond, Pragma, and Renew Medical; royalties from Medtronic, Intuitive Surgical, Karl Storz Endoscopy America, and Unique Surgical Innovations; and inactive consulting relationships with CRH Medical and Intuitive Surgical. Dr de Wilt reported grants from Dutch Cancer Society, ZonMW (The Netherlands Organisation for Health Research and Development), Bergh in het Zadel Foundation, and Medtronic to his institution outside the submitted work. No other disclosures were reported. Publisher Copyright: © 2021 American Medical Association. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Importance: The incidence of early-onset colorectal cancer (younger than 50 years) is rising globally, the reasons for which are unclear. It appears to represent a unique disease process with different clinical, pathological, and molecular characteristics compared with late-onset colorectal cancer. Data on oncological outcomes are limited, and sensitivity to conventional neoadjuvant and adjuvant therapy regimens appear to be unknown. The purpose of this review is to summarize the available literature on early-onset colorectal cancer. Observations: Within the next decade, it is estimated that 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in adults younger than 50 years. Potential risk factors include a Westernized diet, obesity, antibiotic usage, and alterations in the gut microbiome. Although genetic predisposition plays a role, most cases are sporadic. The full spectrum of germline and somatic sequence variations implicated remains unknown. Younger patients typically present with descending colonic or rectal cancer, advanced disease stage, and unfavorable histopathological features. Despite being more likely to receive neoadjuvant and adjuvant therapy, patients with early-onset disease demonstrate comparable oncological outcomes with their older counterparts. Conclusions and Relevance: The clinicopathological features, underlying molecular profiles, and drivers of early-onset colorectal cancer differ from those of late-onset disease. Standardized, age-specific preventive, screening, diagnostic, and therapeutic strategies are required to optimize outcomes.
AB - Importance: The incidence of early-onset colorectal cancer (younger than 50 years) is rising globally, the reasons for which are unclear. It appears to represent a unique disease process with different clinical, pathological, and molecular characteristics compared with late-onset colorectal cancer. Data on oncological outcomes are limited, and sensitivity to conventional neoadjuvant and adjuvant therapy regimens appear to be unknown. The purpose of this review is to summarize the available literature on early-onset colorectal cancer. Observations: Within the next decade, it is estimated that 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in adults younger than 50 years. Potential risk factors include a Westernized diet, obesity, antibiotic usage, and alterations in the gut microbiome. Although genetic predisposition plays a role, most cases are sporadic. The full spectrum of germline and somatic sequence variations implicated remains unknown. Younger patients typically present with descending colonic or rectal cancer, advanced disease stage, and unfavorable histopathological features. Despite being more likely to receive neoadjuvant and adjuvant therapy, patients with early-onset disease demonstrate comparable oncological outcomes with their older counterparts. Conclusions and Relevance: The clinicopathological features, underlying molecular profiles, and drivers of early-onset colorectal cancer differ from those of late-onset disease. Standardized, age-specific preventive, screening, diagnostic, and therapeutic strategies are required to optimize outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85114982910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114982910&partnerID=8YFLogxK
U2 - 10.1001/jamasurg.2021.2380
DO - 10.1001/jamasurg.2021.2380
M3 - Review article
C2 - 34190968
AN - SCOPUS:85114982910
SN - 2168-6254
VL - 156
SP - 865
EP - 874
JO - JAMA Surgery
JF - JAMA Surgery
IS - 9
ER -